MYOV News and Press, Myovant Sciences Ltd. From 05/14/19

Gainers:  Big 5 Sporting Goods (NASDAQ: BGFV ) +26% . Novavax (NASDAQ: NVAX ) +25% . Asta Funding (NASDAQ: ASFI ) +20% . MeiraGTx Holdings (NASDAQ: MGTX ) +19% . Luokung Technology (NASDAQ: LKCO ) +18% . Key Energy Services (NYSE: KEG ) +17% . Verastem (NASDAQ: VSTM ) +17% . Su...

Solid Biosciences (NASDAQ: SLDB )  -41%  on potential safety signals for DMD gene therapy. More news on: Solid Biosciences Inc., Myovant Sciences Ltd., InspireMD, Inc., Stocks on the move, Read more ...

Myovant Sciences (NYSE: MYOV ) perks up  2%  premarket on light volume on the heels of a positive outcom e from a Phase 3 clinical trial, LIBERTY 1 , evaluating relugolix, co-administered with low-dose estradiol and norethindrone, in women with uterine fibroids with heavy menstru...

- Phase 3 study met primary efficacy endpoint with highly statistically significant 73.4% response rate (p < 0.0001); women experienced, on average, an 84.3% reduction in menstrual blood loss - Achieved six key secondary endpoints including reduction in menstrual blood loss (p < 0.000...

BASEL, Switzerland, May 13, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced it will hold a webcast and conference call beg...

The following slide deck was published by Myovant Sciences Ltd. in conjunction with this Read more ...

BASEL, Switzerland , March 5, 2019 /PRNewswire/ -- Myovant Sciences (NYSE:  MYOV ), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Lynn Seely , M.D., President and Chief Executive Officer, will present at the...

Thinly traded Myovant Sciences ( MYOV +12.4% ) is up on double normal volume, albeit on turnover of only 128K shares, on no particular news. The stock has rallied almost  50%  since late December. More news on: Myovant Sciences, Healthcare stocks news, Stocks on the move, R...

Myovant Sciences (NYSE: MYOV ): Q3 GAAP EPS of -$1.04. More news on: Myovant Sciences, Earnings news and commentary, Healthcare stocks news, Read more ...

BASEL, Switzerland , Feb. 7, 2019 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases, today announced corporate update...